title: [Safety of subcutaneous immunotherapy with tyrosine-adsorbed house dust mite extracts in patients with allergic disease].
abstract: In spite of allergen-specific immunotherapy (SIT) multiple benefits, its use is restricted in some countries owing to concerns about severe adverse reactions.
  
  
  
  To evaluate systemic adverse reactions in patients with atopic dermatitis, allergic asthma, allergic rhinitis and allergic conjunctivitis who received subcutaneous immunotherapy with tyrosine-adsorbed Dermatophagoides and Glycyphagoides dust mites extracts.
  
  
  
  Retrospective study of the 2010-2015-period that included 773 patients diagnosed with IgE-mediated diseases, where the safety of allergen-specific immunotherapy was described according to the World Organization of Allergy subcutaneous immunotherapy-induced systemic reactions classification system.
  
  
  
  79.7 % of patients had rhinitis, 54.9 % asthma, 34.5 % conjunctivitis and 16.4 % atopic dermatitis. Out of 12,546 tyrosine-adsorbed extract doses, 45 systemic reactions were recorded: 12 were grade 1 (30 %), 27 grade 2 (67.5 %) and 1 was grade 3 (2.5 %); the reaction rate was 0.35 per 100 administered injections, for an incidence rate of 5.8 %. No fatal reactions occurred.
  
  
  
  The frequency of systemic reactions with subcutaneous immunotherapy with Dermatophagoides farinae, Dermatophagoides pteronyssinus and Blomia tropicalis tyrosine-adsorbed extracts was similar to that reported with other extracts.
authors.affiliation: Universidad de Antioquia, IPS Universitaria, Servicio Alergología Clínica. Grupo de Alergología Clínica y Experimental. Medellín, Colombia. rcv2016udea@gmail.com.
authors.forename: Mónica María
authors.initials: MM
authors.lastname: Molina-Sáenz
authors.forename: Ana María
authors.initials: AM
authors.lastname: Villa-Arango
authors.forename: Ricardo
authors.initials: R
authors.lastname: Cardona-Villa
mesh_terms: D000293:Adolescent; D000327:Adsorption; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D001249:Asthma / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000628:therapy; D003876:Dermatitis, Atopic / Q000628:therapy; D040002:Dermatophagoides pteronyssinus / Q000276:immunology; D003888:Desensitization, Immunologic / Q000009:adverse effects*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012220:Rhinitis / Q000628:therapy; D014443:Tyrosine
chemical_list: D039741:Antigens, Dermatophagoides; D014443:Tyrosine
keywords: Allergy; Dermatophagoides; Immunotherapy; Respiratory disease